1
|
Palma S, Raffa CI, Garcia-Fabiani MB, Ferretti VA, Zwenger A, Perez Verdera PV, Llontop A, Rojas Bilbao E, Cuartero V, Abba MC, Lacunza E. RHBDD2 overexpression promotes a chemoresistant and invasive phenotype to rectal cancer tumors via modulating UPR and focal adhesion genes. Biochim Biophys Acta Mol Basis Dis 2020; 1866:165810. [PMID: 32339641 DOI: 10.1016/j.bbadis.2020.165810] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2019] [Revised: 04/07/2020] [Accepted: 04/19/2020] [Indexed: 12/29/2022]
Abstract
The current standard of care for locally advanced rectal cancer (RC) is neoadjuvant radio-chemotherapy (NRC) with 5-fluorouracil (5Fu) as the main drug, followed by surgery and adjuvant chemotherapy. While a group of patients will achieve a pathological complete response, a significant percentage will not respond to the treatment. The Unfolding Protein Response (UPR) pathway is generally activated in tumors and results in resistance to radio-chemotherapy. We previously showed that RHBDD2 gene is overexpressed in the advanced stages of colorectal cancer (CRC) and that it could modulate the UPR pathway. Moreover, RHBDD2 expression is induced by 5Fu. In this study, we demonstrate that the overexpression of RHBDD2 in CACO2 cell line confers resistance to 5Fu, favors cell migration, adhesion and proliferation and has a profound impact on the expression of both, the UPR genes BiP, PERK and CHOP, and on the cell adhesion genes FAK and PXN. We also determined that RHBDD2 binds to BiP protein, the master UPR regulator. Finally, we confirmed that a high expression of RHBDD2 in RC tumors after NRC treatment is associated with the development of local or distant metastases. The collected evidence positions RHBDD2 as a promising prognostic biomarker to predict the response to neoadjuvant therapy in patients with RC.
Collapse
Affiliation(s)
- S Palma
- Centro de Investigaciones Inmunológicas Básicas y Aplicadas, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina
| | - C I Raffa
- Gastroenterology and Proctology Department, Instituto de Oncología Angel H. Roffo, University of Buenos Aires, Buenos Aires, Argentina
| | - M B Garcia-Fabiani
- Instituto de Investigaciones Bioquímicas de La Plata Rodolfo R. Brenner, CONICET, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina
| | - V A Ferretti
- Centro de Investigaciones Inmunológicas Básicas y Aplicadas, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina
| | - A Zwenger
- Grupo Oncológico Cooperativo del Sur (GOCS), Neuquén, Argentina
| | | | - A Llontop
- Pathology Department, Instituto de Oncología Angel H. Roffo, University of Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - E Rojas Bilbao
- Pathology Department, Instituto de Oncología Angel H. Roffo, University of Buenos Aires, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
| | - V Cuartero
- Clinic Oncology Department, Functional Unit of Digestive Tumors, Instituto de Oncología Angel H. Roffo, University of Buenos Aires, Buenos Aires, Argentina
| | - M C Abba
- Centro de Investigaciones Inmunológicas Básicas y Aplicadas, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina
| | - E Lacunza
- Centro de Investigaciones Inmunológicas Básicas y Aplicadas, Facultad de Ciencias Médicas, Universidad Nacional de La Plata, La Plata, Buenos Aires, Argentina.
| |
Collapse
|
2
|
Gabay C, Rusjan N, Martin K, Bonet M, Rojas Bilbao E, Castro M. P1.15-08 Implementation and Feasibility of the Assessment of EGFR Mutation in NSCLC Using Liquid Biopsy at an Argentinean University Hospital. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
3
|
Wainsztein V, Recondo G, Denninghoff V, Cuello M, Greco M, De La Vega M, Galanternik F, Rojas Bilbao E, Avagnina A, Castro M, Recondo G. P20 Molecular Characterization of Non–Small Cell Lung Cancer (NSCLC) Patients by Next Generation Sequencing: Preliminary Data. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
4
|
Denninghoff V, Wainsztein V, Cuello M, Recondo G, Rojas Bilbao E, Avagnina A, Recondo G. P49 Lung Adenocarcinoma with Double Heterozygote EGFR mutation and Combined Resistance: ALK Translocation and EGFR T790M. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.07.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|